• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Optic Nerve Injury - Pipeline Review, H2 2012 Product Image

Optic Nerve Injury - Pipeline Review, H2 2012

  • ID: 2335105
  • November 2012
  • 33 pages
  • Global Markets Direct

Optic Nerve Injury – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Optic Nerve Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Optic Nerve Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Optic Nerve Injury. Optic Nerve Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Optic Nerve Injury.
- A review of the Optic Nerve Injury products under development by companies and universities/research READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Optic Nerve Injury Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Optic Nerve Injury 7
Optic Nerve Injury Therapeutics under Development by Companies 9
Optic Nerve Injury Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Optic Nerve Injury Therapeutics – Products under Development by Companies 14
Optic Nerve Injury Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Optic Nerve Injury Therapeutics Development 16
Quark Pharmaceuticals, Inc. 16
Alseres Pharmaceuticals, Inc. 17
Proneuron Biotechnologies, Inc. 18
Optic Nerve Injury – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
oncomodulin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
QPI-1007 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Neuroprotection And Neural Regeneration Program - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PN-277 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
unoprostone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Optic Nerve Injury Therapeutics – Drug Profile Updates 30
Optic Nerve Injury Therapeutics - Dormant Products 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Optic Nerve Injury, H2 2012 7
Products under Development for Optic Nerve Injury – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Quark Pharmaceuticals, Inc., H2 2012 16
Alseres Pharmaceuticals, Inc., H2 2012 17
Proneuron Biotechnologies, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Optic Nerve Injury Therapeutics – Drug Profile Updates 30
Optic Nerve Injury Therapeutics – Dormant Products 31

List of Figures
Number of Products under Development for Optic Nerve Injury, H2 2012 7
Products under Development for Optic Nerve Injury – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos